Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Buckey who wrote (113594)	4/9/2003 3:47:40 PM
From: Jim Bishop	Respond to of 150070

NXXI Nutrition 21 Receives Milestone Payment for New Drug Candidate Wednesday April 9, 3:44 pm ET Biosynexus Makes Clinical Trial Milestone Payment to Nutrition 21 PURCHASE, N.Y.--(BUSINESS WIRE)--April 9, 2003--Nutrition 21, Inc. (Nasdaq: NXXI - News) today announced that Biosynexus Inc. of Rockville, MD, made a clinical trial milestone payment to Nutrition 21. Biosynexus is Nutrition 21's licensee for nisin and lysostaphin antibacterial technologies for development and marketing of new drugs for human use. Biosynexus develops products for the prevention and treatment of serious bacterial infections. Biosynexus as a result of initiating a clinical trial, made its first milestone payment to Nutrition 21. The Biosynexus Agreements provide for future payments to Nutrition 21 of up to $14 million, contingent upon the achievement by Biosynexus of certain additional milestones; royalties to Nutrition 21 upon commercialization of human drug products from these technologies; and potential other consideration contingent on future transactions between Biosynexus and third parties that relate to nisin or lysostaphin. Gail Montgomery, Nutrition 21's president and chief executive officer, said, "Our business strategy is to leverage our intellectual property portfolio for maximum return to our shareholders. We are pleased to be working with Biosynexus, who has demonstrated its abilities to further Nutrtion 21's patented technologies, having reached an important milestone in commercializing lysostaphin as a therapy for the prevention and treatment of infections caused by antibiotic resistant bacteria." According to the Institute of Medicine as many as 100,000 annual deaths are attributable to preventable adverse patient events associated with hospital acquired antibiotic resistant infections, at an estimated cost of $17-$29 billion. About Nutrition 21 Nutrition 21 is a leading developer and provider of nutritional products whose health benefits are substantiated by clinical research. The market leader in nutritional chromium, Nutrition 21 currently holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at www.nutrition21.com. -------------------------------------------------------------------------------- Contact: Nutrition 21, Inc. Stacey Antine, 914/701-4567 -------------------------------------------------------------------------------- Source: Nutrition 21, Inc.